Advances in HIV Alternative Splicing
What complex regulatory mechanisms the Human Immunodeficiency Virus uses to maximize its small genome.
5/12/20262 min read
Presented by Prof. Heiner Schaal from the Heinrich Heiner University of Düsseldorf, the talk served as the inaugural seminar for RNA Salon Kenya, signaling a focus on high-level transcriptomics and virology. A primary talking point was been the splicing code, the set of rules governing how a single 9kb viral transcript is processed into over 40 different mRNA species. Prof. Schaal discussed how HIV-1 balances this alternative splicing to ensure the production of structural proteins, regulatory factors like Tat and Rev, and the genomic RNA itself, all while avoiding over-splicing which would render the virus sterile.
The technical core of the webinar delved into the classification of these transcripts into three major groups: the 9kb unspliced genome (for Gag/Pol), the 4kb partially spliced group (for Vif, Vpr, Vpu, and Env), and the 2kb completely spliced group (for Tat, Rev, and Nef). It was explained that because cells naturally tend to splice or degrade intron-containing RNAs, HIV-1 must decipher and manipulate host machinery to bypass these policing mechanisms. This involves a sophisticated interplay between viral cis-acting elements, such as Exonic Splicing Enhancers (ESE) and Silencers (ESS) and host trans-acting factors like SR proteins and hnRNPs that bind to them.
The presentation highlighted how modern technologies are used to map this code. The use of Next-Generation Sequencing (NGS) and deep-sequencing assays was discussed to quantify splice site usage with high precision. This quantitative approach allows researchers to identify even low-frequency splice variants and understand how specific mutations or cellular environments (like different T-cell types) alter the viral transcript pool. These insights are crucial because any disruption to the delicate ratio of these messages can significantly impair viral replication and infectivity.
Finally, the webinar concluded with the therapeutic potential of targeting the HIV-1 splicing machinery. Since the virus has an absolute requirement for precise alternative splicing to form infectious particles, this process represents a bottleneck and a promising target for a new class of antiviral drugs. By using small molecules or oligonucleotides to induce over-splicing or block specific acceptors, researchers hope to stall viral development entirely. The seminar's location at KEMRI underscores the importance of bringing these cutting-edge molecular insights to the regional scientific community to foster local expertise in RNA-based drug discovery